Patents by Inventor Weihong ZHUANG

Weihong ZHUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11213493
    Abstract: A topical preparation containing vitamin K1 and a preparation method thereof are provided. The topical preparation includes the following components in weight percentage: 0.01-5% of vitamin K1, 0.1-25% of a transdermal enhancer and 70-99% of a matrix for the topical preparation. The transdermal enhancer is composed of urea, menthol and Eucalyptus oil in a mass ratio of (5-6):(2-3):(1-3). The topical preparation containing vitamin K1 can be used to treat moderate and severe skin toxicity caused by anti-tumor drugs related to epidermal growth factor receptor (EGFR), can effectively treat diseases such as acne-like rash, pruritus, red swelling, dry skin and mucositis caused by EGFR-related anti-tumor drugs, and can ensure the continued treatment with anti-EGFR targeting drugs. It can increase the possibility of vitamin K1 reaching focus sites in the dermal layer through the stratum corneum, and can rapidly alleviate moderate and severe skin diseases caused by EGFR-related anti-tumor drugs.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: January 4, 2022
    Assignee: YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL CO., LTD.
    Inventors: Haihua Ni, Xinguo Jiang, Feng Jiang, Yun Xu, Xin Pan, Weihong Zhuang
  • Publication number: 20210015766
    Abstract: A topical preparation containing vitamin K1 and a preparation method thereof are provided. The topical preparation includes the following components in weight percentage: 0.01-5% of vitamin K1, 0.1-25% of a transdermal enhancer and 70-99% of a matrix for the topical preparation. The transdermal enhancer is composed of urea, menthol and eucalyptus oil in a mass ratio of (5-6):(2-3):(1-3). The topical preparation containing vitamin K1 can be used to treat moderate and severe skin toxicity caused by anti-tumor drugs related to epidermal growth factor receptor (EGFR), can effectively treat diseases such as acne-like rash, pruritus, red swelling, dry skin and mucositis caused by EGFR-related anti-tumor drugs, and can ensure the continued treatment with anti-EGFR targeting drugs. It can increase the possibility of vitamin K1 reaching focus sites in the dermal layer through the stratum corneum, and can rapidly alleviate moderate and severe skin diseases caused by EGFR-related anti-tumor drugs.
    Type: Application
    Filed: November 4, 2019
    Publication date: January 21, 2021
    Applicant: YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL CO., LTD.
    Inventors: Haihua NI, Xinguo JIANG, Feng JIANG, Yun XU, Xin PAN, Weihong ZHUANG